0

Close
 
Upcoming Allied Market Research
2023
Biopharmaceuticals Manufacturing Consumables Testing Market

Biopharmaceuticals Manufacturing Consumables Testing Market: Global Opportunity Analysis and Industry Forecast, 2021-2030 Market

LS : Pharmaceuticals
Report Code: A12316
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Biopharmaceuticals Manufacturing Consumables Testing Market

Request Now !

Biopharmaceuticals Manufacturing Consumables Testing Market Statistics 2030:

Consumables are key materials that are used in support of manufacturing or which come in contact with the product during manufacturing that may not become part of final product. In biopharmaceuticals, two types of consumables available in the market are direct and indirect quality impacting consumables. The former includes product filters, product tubing, process gases, and polyethylene bags, which will have direct contact with product and directly affect the quality and safety of the final product.  The indirect quality impacting consumables do not come into direct contact with the product but may affect the quality of the product that include gloves and garments.  Various government norms and regulations as well as internal standards have been imposed to ensure proper testing of these consumables to meet product quality and safety needs.

COVID-19 scenario analysis

The ongoing global COVID-19 pandemic has diversely impacted healthcare markets either positively or negatively. To curb the spread of novel coronavirus, countries are imposing strict lockdown, therefore leading to shutting down of manufacturing units. As biopharmaceuticals manufacturing consumables testing is important to check the purity and safety of a drug, key players are focusing on the manufacture of COVID-19 vaccine, which will certainly effect the production of biopharmaceuticals manufacturing consumables in a positive way.

Top impacting factors: market scenario analysis, trends, drivers, and impact analysis

The factors responsible for the growth of are the expansion of biopharmaceutical industry across the globe, rise in expenditure by the biopharmaceutical companies on the research and development activities for the development of new and effective drugs, surge in need for in depth testing of raw materials before product launch. Moreover, there have been rapid advancements taking place in terms of new testing equipment released by key players causing the market to proliferate at a rapid pace.

However, lack of expertise regarding operations associated with production of testing equipment and high costs of deploying necessary equipment to manufacture testing machineries and instruments will create major challenge to the growth of the biopharmaceuticals manufacturing consumables testing market.

Key benefits of the report

  • This study presents the analytical depiction of the global biopharmaceuticals manufacturing consumables testing market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the biopharmaceuticals manufacturing consumables testing market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed biopharmaceuticals manufacturing consumables testing market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions answered in the biopharmaceuticals manufacturing consumables testing market research report

  • Which are the leading players active in the biopharmaceuticals manufacturing consumables testing market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?

 Biopharmaceuticals Manufacturing Consumables Testing Market: Global Opportunity Analysis and Industry Forecast, 2021–2030 Report Highlights

Aspects Details
By Type
  • Chemical Analysis Testing
  • Enzyme Testing
  • Stability Testing
  • Sterility Testing
  • Others
By Raw Material
  • Formulation Excipients
  • Active Pharmaceutical Ingredients (API)
  • Compendial methods (USP/EP/JP) Based
  • Vendor Qualification Program Support
By Application
  • Pharma and Biological
  • Medical Devices
  • Others
By End User
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Eurofins Scientific, Pace Analytical Services, LLC, Gibraltar Laboratories., Avomeen Analytical Services, Merck KGaA, Agilent Technologies, Charles River, BioSpectra, Catalent, Inc., Alcami Corporation
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Chemical Analysis Testing

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Enzyme Testing

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Stability Testing

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Sterility Testing

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, BY RAW MATERIAL

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Raw Material

    • 5.2. Formulation Excipients

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Active Pharmaceutical Ingredients (API)

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Compendial Methods (USP/EP/JP) Based

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Vendor Qualification Program Support

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, BY APPLICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Application

    • 6.2. Pharma And Biological

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Medical Devices

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Pharmaceutical And Biotechnology Companies

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Academic And Research Institutes

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Contract Development And Manufacturing Organizations (CDMOs)

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

    • 7.5. Others

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

  • CHAPTER 8: BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Type

      • 8.2.3. Market Size and Forecast, By Raw Material

      • 8.2.4. Market Size and Forecast, By Application

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.2.7.1. Market Size and Forecast, By Type
        • 8.2.7.2. Market Size and Forecast, By Raw Material
        • 8.2.7.3. Market Size and Forecast, By Application
        • 8.2.7.4. Market Size and Forecast, By End User

      • 8.2.8. Canada Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.2.8.1. Market Size and Forecast, By Type
        • 8.2.8.2. Market Size and Forecast, By Raw Material
        • 8.2.8.3. Market Size and Forecast, By Application
        • 8.2.8.4. Market Size and Forecast, By End User

      • 8.2.9. Mexico Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.2.9.1. Market Size and Forecast, By Type
        • 8.2.9.2. Market Size and Forecast, By Raw Material
        • 8.2.9.3. Market Size and Forecast, By Application
        • 8.2.9.4. Market Size and Forecast, By End User

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Type

      • 8.3.3. Market Size and Forecast, By Raw Material

      • 8.3.4. Market Size and Forecast, By Application

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.3.7.1. Market Size and Forecast, By Type
        • 8.3.7.2. Market Size and Forecast, By Raw Material
        • 8.3.7.3. Market Size and Forecast, By Application
        • 8.3.7.4. Market Size and Forecast, By End User

      • 8.3.8. Germany Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.3.8.1. Market Size and Forecast, By Type
        • 8.3.8.2. Market Size and Forecast, By Raw Material
        • 8.3.8.3. Market Size and Forecast, By Application
        • 8.3.8.4. Market Size and Forecast, By End User

      • 8.3.9. Italy Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.3.9.1. Market Size and Forecast, By Type
        • 8.3.9.2. Market Size and Forecast, By Raw Material
        • 8.3.9.3. Market Size and Forecast, By Application
        • 8.3.9.4. Market Size and Forecast, By End User

      • 8.3.10. Spain Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.3.10.1. Market Size and Forecast, By Type
        • 8.3.10.2. Market Size and Forecast, By Raw Material
        • 8.3.10.3. Market Size and Forecast, By Application
        • 8.3.10.4. Market Size and Forecast, By End User

      • 8.3.11. UK Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.3.11.1. Market Size and Forecast, By Type
        • 8.3.11.2. Market Size and Forecast, By Raw Material
        • 8.3.11.3. Market Size and Forecast, By Application
        • 8.3.11.4. Market Size and Forecast, By End User

      • 8.3.12. Russia Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.3.12.1. Market Size and Forecast, By Type
        • 8.3.12.2. Market Size and Forecast, By Raw Material
        • 8.3.12.3. Market Size and Forecast, By Application
        • 8.3.12.4. Market Size and Forecast, By End User

      • 8.3.13. Rest Of Europe Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.3.13.1. Market Size and Forecast, By Type
        • 8.3.13.2. Market Size and Forecast, By Raw Material
        • 8.3.13.3. Market Size and Forecast, By Application
        • 8.3.13.4. Market Size and Forecast, By End User

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Type

      • 8.4.3. Market Size and Forecast, By Raw Material

      • 8.4.4. Market Size and Forecast, By Application

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.4.7.1. Market Size and Forecast, By Type
        • 8.4.7.2. Market Size and Forecast, By Raw Material
        • 8.4.7.3. Market Size and Forecast, By Application
        • 8.4.7.4. Market Size and Forecast, By End User

      • 8.4.8. Japan Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.4.8.1. Market Size and Forecast, By Type
        • 8.4.8.2. Market Size and Forecast, By Raw Material
        • 8.4.8.3. Market Size and Forecast, By Application
        • 8.4.8.4. Market Size and Forecast, By End User

      • 8.4.9. India Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.4.9.1. Market Size and Forecast, By Type
        • 8.4.9.2. Market Size and Forecast, By Raw Material
        • 8.4.9.3. Market Size and Forecast, By Application
        • 8.4.9.4. Market Size and Forecast, By End User

      • 8.4.10. South Korea Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.4.10.1. Market Size and Forecast, By Type
        • 8.4.10.2. Market Size and Forecast, By Raw Material
        • 8.4.10.3. Market Size and Forecast, By Application
        • 8.4.10.4. Market Size and Forecast, By End User

      • 8.4.11. Australia Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.4.11.1. Market Size and Forecast, By Type
        • 8.4.11.2. Market Size and Forecast, By Raw Material
        • 8.4.11.3. Market Size and Forecast, By Application
        • 8.4.11.4. Market Size and Forecast, By End User

      • 8.4.12. Thailand Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.4.12.1. Market Size and Forecast, By Type
        • 8.4.12.2. Market Size and Forecast, By Raw Material
        • 8.4.12.3. Market Size and Forecast, By Application
        • 8.4.12.4. Market Size and Forecast, By End User

      • 8.4.13. Malaysia Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.4.13.1. Market Size and Forecast, By Type
        • 8.4.13.2. Market Size and Forecast, By Raw Material
        • 8.4.13.3. Market Size and Forecast, By Application
        • 8.4.13.4. Market Size and Forecast, By End User

      • 8.4.14. Indonesia Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.4.14.1. Market Size and Forecast, By Type
        • 8.4.14.2. Market Size and Forecast, By Raw Material
        • 8.4.14.3. Market Size and Forecast, By Application
        • 8.4.14.4. Market Size and Forecast, By End User

      • 8.4.15. Rest of Asia Pacific Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.4.15.1. Market Size and Forecast, By Type
        • 8.4.15.2. Market Size and Forecast, By Raw Material
        • 8.4.15.3. Market Size and Forecast, By Application
        • 8.4.15.4. Market Size and Forecast, By End User

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Type

      • 8.5.3. Market Size and Forecast, By Raw Material

      • 8.5.4. Market Size and Forecast, By Application

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.5.7.1. Market Size and Forecast, By Type
        • 8.5.7.2. Market Size and Forecast, By Raw Material
        • 8.5.7.3. Market Size and Forecast, By Application
        • 8.5.7.4. Market Size and Forecast, By End User

      • 8.5.8. South Africa Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.5.8.1. Market Size and Forecast, By Type
        • 8.5.8.2. Market Size and Forecast, By Raw Material
        • 8.5.8.3. Market Size and Forecast, By Application
        • 8.5.8.4. Market Size and Forecast, By End User

      • 8.5.9. Saudi Arabia Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.5.9.1. Market Size and Forecast, By Type
        • 8.5.9.2. Market Size and Forecast, By Raw Material
        • 8.5.9.3. Market Size and Forecast, By Application
        • 8.5.9.4. Market Size and Forecast, By End User

      • 8.5.10. UAE Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.5.10.1. Market Size and Forecast, By Type
        • 8.5.10.2. Market Size and Forecast, By Raw Material
        • 8.5.10.3. Market Size and Forecast, By Application
        • 8.5.10.4. Market Size and Forecast, By End User

      • 8.5.11. Argentina Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.5.11.1. Market Size and Forecast, By Type
        • 8.5.11.2. Market Size and Forecast, By Raw Material
        • 8.5.11.3. Market Size and Forecast, By Application
        • 8.5.11.4. Market Size and Forecast, By End User

      • 8.5.12. Rest of LAMEA Biopharmaceuticals Manufacturing Consumables Testing Market

        • 8.5.12.1. Market Size and Forecast, By Type
        • 8.5.12.2. Market Size and Forecast, By Raw Material
        • 8.5.12.3. Market Size and Forecast, By Application
        • 8.5.12.4. Market Size and Forecast, By End User

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Alcami Corporation

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Merck KGaA

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Eurofins Scientific

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Agilent Technologies

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Charles River

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Catalent, Inc.

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Avomeen Analytical Services

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. BioSpectra

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Pace Analytical Services, LLC

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Gibraltar Laboratories.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR CHEMICAL ANALYSIS TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR ENZYME TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR STABILITY TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR STERILITY TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR FORMULATION EXCIPIENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENTS (API), BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR COMPENDIAL METHODS (USP/EP/JP) BASED, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR VENDOR QUALIFICATION PROGRAM SUPPORT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR PHARMA AND BIOLOGICAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR MEDICAL DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. U.S. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. U.S. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 29. U.S. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. U.S. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. CANADA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. CANADA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 33. CANADA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. CANADA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. MEXICO BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. GERMANY BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 50. GERMANY BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. GERMANY BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ITALY BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. ITALY BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 54. ITALY BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. ITALY BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. SPAIN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. UK BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 61. UK BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 62. UK BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. UK BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. RUSSIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. RUSSIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 66. RUSSIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. RUSSIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. REST OF EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 70. REST OF EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. REST OF EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 73. ASIA-PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 75. ASIA-PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. ASIA-PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. CHINA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 78. CHINA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 79. CHINA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. CHINA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 81. JAPAN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 82. JAPAN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 83. JAPAN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 84. JAPAN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 85. INDIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 86. INDIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 87. INDIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. INDIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH KOREA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH KOREA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. AUSTRALIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 94. AUSTRALIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 95. AUSTRALIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 96. AUSTRALIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 97. THAILAND BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 98. THAILAND BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 99. THAILAND BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 100. THAILAND BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 101. MALAYSIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 102. MALAYSIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 103. MALAYSIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 104. MALAYSIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 105. INDONESIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 106. INDONESIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 107. INDONESIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 108. INDONESIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 111. REST OF ASIA PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 112. REST OF ASIA PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 113. LAMEA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 114. LAMEA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 116. LAMEA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 117. LAMEA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 118. BRAZIL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 119. BRAZIL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 120. BRAZIL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 121. BRAZIL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 122. SOUTH AFRICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 123. SOUTH AFRICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 124. SOUTH AFRICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 125. SOUTH AFRICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 126. SAUDI ARABIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 127. SAUDI ARABIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 128. SAUDI ARABIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 129. SAUDI ARABIA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 130. UAE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 131. UAE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 132. UAE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 133. UAE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 134. ARGENTINA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 135. ARGENTINA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 136. ARGENTINA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 137. ARGENTINA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 138. REST OF LAMEA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 139. REST OF LAMEA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY RAW MATERIAL, 2022-2032 ($MILLION)
  • TABLE 140. REST OF LAMEA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 141. REST OF LAMEA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 142. ALCAMI CORPORATION: KEY EXECUTIVES
  • TABLE 143. ALCAMI CORPORATION: COMPANY SNAPSHOT
  • TABLE 144. ALCAMI CORPORATION: OPERATING SEGMENTS
  • TABLE 145. ALCAMI CORPORATION: PRODUCT PORTFOLIO
  • TABLE 146. ALCAMI CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. MERCK KGAA: KEY EXECUTIVES
  • TABLE 148. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 149. MERCK KGAA: OPERATING SEGMENTS
  • TABLE 150. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 151. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. EUROFINS SCIENTIFIC: KEY EXECUTIVES
  • TABLE 153. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 154. EUROFINS SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 155. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 156. EUROFINS SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. AGILENT TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 158. AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 159. AGILENT TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 160. AGILENT TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 161. AGILENT TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. CHARLES RIVER: KEY EXECUTIVES
  • TABLE 163. CHARLES RIVER: COMPANY SNAPSHOT
  • TABLE 164. CHARLES RIVER: OPERATING SEGMENTS
  • TABLE 165. CHARLES RIVER: PRODUCT PORTFOLIO
  • TABLE 166. CHARLES RIVER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. CATALENT, INC.: KEY EXECUTIVES
  • TABLE 168. CATALENT, INC.: COMPANY SNAPSHOT
  • TABLE 169. CATALENT, INC.: OPERATING SEGMENTS
  • TABLE 170. CATALENT, INC.: PRODUCT PORTFOLIO
  • TABLE 171. CATALENT, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 172. AVOMEEN ANALYTICAL SERVICES: KEY EXECUTIVES
  • TABLE 173. AVOMEEN ANALYTICAL SERVICES: COMPANY SNAPSHOT
  • TABLE 174. AVOMEEN ANALYTICAL SERVICES: OPERATING SEGMENTS
  • TABLE 175. AVOMEEN ANALYTICAL SERVICES: PRODUCT PORTFOLIO
  • TABLE 176. AVOMEEN ANALYTICAL SERVICES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. BIOSPECTRA: KEY EXECUTIVES
  • TABLE 178. BIOSPECTRA: COMPANY SNAPSHOT
  • TABLE 179. BIOSPECTRA: OPERATING SEGMENTS
  • TABLE 180. BIOSPECTRA: PRODUCT PORTFOLIO
  • TABLE 181. BIOSPECTRA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182. PACE ANALYTICAL SERVICES, LLC: KEY EXECUTIVES
  • TABLE 183. PACE ANALYTICAL SERVICES, LLC: COMPANY SNAPSHOT
  • TABLE 184. PACE ANALYTICAL SERVICES, LLC: OPERATING SEGMENTS
  • TABLE 185. PACE ANALYTICAL SERVICES, LLC: PRODUCT PORTFOLIO
  • TABLE 186. PACE ANALYTICAL SERVICES, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 187. GIBRALTAR LABORATORIES.: KEY EXECUTIVES
  • TABLE 188. GIBRALTAR LABORATORIES.: COMPANY SNAPSHOT
  • TABLE 189. GIBRALTAR LABORATORIES.: OPERATING SEGMENTS
  • TABLE 190. GIBRALTAR LABORATORIES.: PRODUCT PORTFOLIO
  • TABLE 191. GIBRALTAR LABORATORIES.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET
  • FIGURE 3. SEGMENTATION BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALBIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET
  • FIGURE 11. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR CHEMICAL ANALYSIS TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR ENZYME TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR STABILITY TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR STERILITY TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SEGMENTATION, BY BY RAW MATERIAL
  • FIGURE 18. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR FORMULATION EXCIPIENTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENTS (API), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR COMPENDIAL METHODS (USP/EP/JP) BASED, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR VENDOR QUALIFICATION PROGRAM SUPPORT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 23. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR PHARMA AND BIOLOGICAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SEGMENTATION, BY BY END USER
  • FIGURE 27. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 32. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 33. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 34. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 35. COMPETITIVE DASHBOARD
  • FIGURE 36. COMPETITIVE HEATMAP: BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET
  • FIGURE 37. Top player positioning, 2022
  • FIGURE 38. ALCAMI CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. ALCAMI CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. ALCAMI CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. MERCK KGAA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. MERCK KGAA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. EUROFINS SCIENTIFIC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. EUROFINS SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. EUROFINS SCIENTIFIC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. AGILENT TECHNOLOGIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. AGILENT TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. AGILENT TECHNOLOGIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. CHARLES RIVER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. CHARLES RIVER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. CHARLES RIVER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. CATALENT, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. CATALENT, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. CATALENT, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. AVOMEEN ANALYTICAL SERVICES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. AVOMEEN ANALYTICAL SERVICES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. AVOMEEN ANALYTICAL SERVICES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. BIOSPECTRA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. BIOSPECTRA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. BIOSPECTRA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. PACE ANALYTICAL SERVICES, LLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. PACE ANALYTICAL SERVICES, LLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. PACE ANALYTICAL SERVICES, LLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 65. GIBRALTAR LABORATORIES.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. GIBRALTAR LABORATORIES.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 67. GIBRALTAR LABORATORIES.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Biopharmaceuticals Manufacturing Consumables Testing Market

Start reading.
This Report and over 66,783+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers